Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients-Reference-Cited by-同舟云学术

Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients

Published:2019-08-29 Issue:5 Volume:84 Page:977-986
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nuthalapati Silpa,Stodtmann Sven,Shepherd Stacie Peacock,Ratajczak Christine K.,Mensing Sven,Menon Rajeev,Xiong Hao

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03930-2.pdf

Reference32 articles.

1. de Murcia G, Menissier-de Murcia J, Schreiber V (1991) Poly(ADP-ribose) polymerase: molecular biological aspects. BioEssays 13(9):455–462. https://doi.org/10.1002/bies.950130905

2. D’Amours D, Desnoyers S, D’Silva I, Poirier GG (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2):249–268

3. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277(25):23028–23036. https://doi.org/10.1074/jbc.m202390200

4. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13(9):2728–2737. https://doi.org/10.1158/1078-0432.ccr-06-3039

5. Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V (2017) Randomized, placebo-controlled, Phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer. Clin Cancer Res 23(8):1937–1944. https://doi.org/10.1158/1078-0432.ccr-15-3069

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomics in ‘Personalised’ Management of Breast Carcinoma;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

2. Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA ‐Mutated Advanced Breast Cancer (BROCADE3) Trial;The Journal of Clinical Pharmacology;2022-05-05

3. Targeting biologically specific molecules in triple negative breast cancer (TNBC);Combinational Therapy in Triple Negative Breast Cancer;2022

4. A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients;The Journal of Clinical Pharmacology;2021-06-19

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer

;Cancer Management and Research;2020-09